Truist Financial Maintains Coherus BioSciences(CHRS.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Jasper Therapeutics (JSPR) and Coherus Biosciences (CHRS)
The Market Doesn't Like What It Sees From Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Revenues Yet As Shares Tumble 28%
JonesTrading Maintains Coherus BioSciences(CHRS.US) With Buy Rating
Short Interest Surges to 21.83% as Coherus BioSciences, Inc. (CHRS) Faces Revenue Challenges
Institutional Owners May Take Dramatic Actions as Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Recent 12% Drop Adds to One-year Losses
Baird Maintains Coherus BioSciences(CHRS.US) With Buy Rating, Maintains Target Price $8
Baird analyst Colleen M. Kusy maintains $Coherus BioSciences(CHRS.US)$ with a buy rating, and maintains the target price at $8.According to TipRanks data, the analyst has a success rate of 34.8% and
Top Midday Decliners
HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $12 Price Target
Truist Financial Maintains Coherus BioSciences(CHRS.US) With Buy Rating
Truist Financial analyst Srikripa Devarakonda maintains $Coherus BioSciences(CHRS.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 58.4% and a total average
H.C. Wainwright Maintains Coherus BioSciences(CHRS.US) With Buy Rating, Maintains Target Price $12
H.C. Wainwright analyst Douglas Tsao maintains $Coherus BioSciences(CHRS.US)$ with a buy rating, and maintains the target price at $12.According to TipRanks data, the analyst has a success rate of 45.
Maintaining Buy Rating on Coherus Biosciences Amid Temporarily Disrupted Supply Chain
Coherus Biosciences Manages UDENYCA Supply Interruption and Cost Reductions
Express News | Coherus BioSciences - Engaged Additional Final Packaging & Labeling Cmo, to Manufacture Udenyca by 2024 End
Express News | Coherus BioSciences Inc - Company Projects That These Actions Will Collectively Reduce Production Cost of Udenyca by Approximately One-Third From Current Levels
Express News | Coherus BioSciences - to Work With Wholesalers & Prescribers to Minimize Any Disruption From Temporary Supply Interruption
Express News | Coherus BioSciences Inc - Projects Channel Supply Udenyca to Be Substantially Depleted by Mid-October as Inventories Draw Down
Express News | Coherus BioSciences: A 3Rd-Party Cmo Said Capacity Constraints at Final Labeling & Packaging Facility to Cause Temporary Udenyca Supply Interruption
Barclays Maintains Coherus BioSciences(CHRS.US) With Buy Rating, Maintains Target Price $7
Barclays analyst Balaji Prasad maintains $Coherus BioSciences(CHRS.US)$ with a buy rating, and maintains the target price at $7.According to TipRanks data, the analyst has a success rate of 49.1%
Barclays Keeps Their Buy Rating on Coherus Biosciences (CHRS)